title: HLA-G expression is irrelevant to prognosis in patients with acute myeloid leukemia.
abstract: Human leukocyte antigen (HLA)-G could contribute to escape of cancer cells from host anti-tumor responses, and its potential clinical relevance in various malignancies was also addressed. However, the prognostic value of HLA-G in acute myeloid leukemia (AML) remains debated. In this study, HLA-G expression in malignant blasts was analyzed from 77 de novo AML patients (AML-M2, n=26; AML-M3, n=24; AML-M4, n=10; AML-M5, n=17) with flow cytometry. The proportion of HLA-G expressing blasts varied from 0% to 93.96% (median: 0.42%; 95% CI: 0-89.0%). Blasts with 0.5% or fewer HLA-G expressing were defined as negative according to its expression in normal CD34(+)CD45(+) cells (n=20, range: 0-0.5%; median: 0.13%; 95% CI: 0-0.42%). HLA-G expression status on leukemic blasts was not associated with the clinical parameters such as patient age at diagnosis, sex, sub-type of AML, percentage of blasts at diagnosis. Survival analysis revealed that HLA-G expression status on leukemic blasts is unrelated to the prognosis (p=0.884). The mean overall survival time for the HLA-G negative and positive patients was 20.7 months (95% CI: 16.1-25.3) and 20.1 months (95% CI: 14.3-25.8), respectively. Taken together, our findings indicated that HLA-G expression is of no significance for the prognosis of patients with AML.
authors.affiliation: Department of Hematology, Taizhou Hospital of Zhejiang Province, Wenzhou Medical College, Linhai, Zhejiang, China.
authors.forename: Q Y
authors.initials: QY
authors.lastname: Guo
authors.forename: B G
authors.initials: BG
authors.lastname: Chen
authors.forename: Y Y
authors.initials: YY
authors.lastname: Ruan
authors.forename: A
authors.initials: A
authors.lastname: Lin
authors.forename: W H
authors.initials: WH
authors.lastname: Yan
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D018952:Antigens, CD34 / Q000096:biosynthesis* / Q000276:immunology; D002648:Child; D005260:Female; D005434:Flow Cytometry; D015870:Gene Expression; D059951:HLA-G Antigens / Q000032:analysis / Q000235:genetics / Q000276:immunology; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis* / Q000235:genetics / Q000276:immunology / Q000401:mortality / Q000473:pathology; D017493:Leukocyte Common Antigens / Q000096:biosynthesis* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D012720:Severity of Illness Index; D012737:Sex Factors; D016019:Survival Analysis; D013601:T-Lymphocytes / Q000276:immunology* / Q000473:pathology
chemical_list: D018952:Antigens, CD34; D059951:HLA-G Antigens; D017493:Leukocyte Common Antigens